Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Internal meetings

- PMLiVE

Smarter Learning and Better Outcomes: How AI Can Provide an Advantage in Medical Education

See how AI-powered patient avatars allow physicians to test complex diagnoses and treatment plans in a simulated environment.

Impetus Digital

- PMLiVE

Lundbeck completes patient randomisation for phase 3 trial for multiple system atrophy treatment

The rare neurodegenerative disorder has no cure and no approved treatments

phthalmologist, optometrist checking child, little girl vision looking for problems and caring for eye

Why patient engagement must come first in rare disease trials

Explore why patient engagement is the cornerstone of successful rare disease trials, emphasising the importance of designing studies around the realities of patients' lives to build trust and improve outcomes.

Cuttsy + Cuttsy

Fan image of Site Report

New Cuttsy+Cuttsy research shows why site support matters more than ever

Cuttsy+Cuttsy's upcoming report, 'The site factor: Where protocol meets practice in clinical trials', delves into the critical role of site staff in clinical research, offering insights into their daily challenges,...

Cuttsy + Cuttsy

- PMLiVE

Turn payer insights into impact with omnichannel engagement in market access

By Betty Charleshouse

Amiculum

- PMLiVE

New Webinar: 2026 Engagement Strategies For Modern Pharma

Turn interaction into intelligence! Don’t miss this chance to lead the industry with our free pharma-exclusive webinar!

Impetus Digital

Photo of Tim Wright plus title of talk

MFN Pricing Is Moving Fast – Here’s What Matters

With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it's a lot to digest. In a new...

Genesis Research Group

- PMLiVE

Genentech reports positive trial results for obesity treatment

The treatment is designed to tackle obesity by reducing appetite and regulating blood sugar

- PMLiVE

ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment

In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on...

Genesis Research Group

- PMLiVE

Sanofi’s amlitelimab shows positive results in atopic dermatitis

Newly released study data shows consistent reductions in disease severity

- PMLiVE

Moderna and Merck announce data from melanoma combination therapy study

Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths

- PMLiVE

AstraZeneca’s Saphnelo demonstrates positive results in systemic lupus erythematosus

Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links